Dimerix, Takeda Cambridge ink research agreement

Previously, Dimerix signed an agreement with Takeda on 15 April 2010.

As per the terms of the agreement, Dimerix will continue using its GPCR-HIT platform and insights into the ability of G Protein-Coupled Receptors (GPCRs) to form complexes, called heteromers, to work with additional undisclosed GPCRs of interest to Takeda.

Takeda Cambridge president Mark Carlton said they have seen that the insights generated using GPCR-HIT provide them with an important extension to their GPCR drug discovery efforts.

Dimerix CEO Tim Grogan said the relevance of their GPCR-HIT platform to the drug discovery and development process and the insights into the formation of complexes between G Protein-Coupled Receptors have been recognized again through the partnership with Takeda Cambridge.